Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> BACKGROUND</h3><p>Although both PSA nadir (PSAn) and testosterone levels at PSA failure are known prognostic factors in men undergoing radiation therapy (RT) and androgen deprivation therapy (ADT) for unfavorable‐risk prostate cancer (PC), it is unclear whether their prognostic significance is independent or overlapping.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> METHODS</h3><p>Seventy‐five men treated with RT with or without 6 months of ADT for unfavorable‐risk nonmetastatic PC enrolled in 2 prospective clinical trials between 1986 and 2001 formed the study cohort. Competing risks and Cox multivariable regression were used to assess whether low versus normal serum testosterone at the time of PSA failure and higher PSAn after initial therapy were independently associated with the risk of PC‐specific (PCSM) and all‐cause mortality (ACM) adjusting for PC prognostic factors.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> RESULTS</h3><p>After a median follow‐up of 15.34 years (interquartile range, 6.66‐16.88 years), there were 53 deaths (73.3%): 30 (56.6%) were from PC. Low testosterone at PSA failure was significantly associated with an increased risk of PCSM (adjusted HR [AHR], 7.77; 95% CI, 1.14‐52.99; <i>P</i> = .04) and ACM (AHR, 3.01; 95% CI, 1.01‐8.96; <i>P</i> = .05), as was higher PSAn (PCSM AHR, 1.03; 95% CI, 1.01‐1.05; <i>P</i> < .01; ACM AHR, 1.04; 95% CI, 1.02‐1.07; <i>P</i> < .01), although the prognostic significance of PSAn was only noted in men with a normal testosterone at PSA failure. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> CONCLUSIONS</h3><p>Low testosterone level at PSA failure in high‐risk patients with PC treated with RT is associated with increased PCSM and ACM risk. In men with normal testosterone levels at the time of PSA failure, an elevated PSAn was associated with worse PCSM and ACM risk.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> LAY SUMMARY</h3><p>This study investigates whether the prostate‐specific antigen (PSA) nadir and normal versus low testosterone at the time of PSA failure provide mutually exclusive or overlapping prognostic information following treatment with radiation and androgen deprivation therapy for unfavorable‐risk patients with prostate cancer using data from 2 prospective clinical trials. It was found that both provided prognostic information; however, higher PSA nadir was only found to be of prognostic significance in men with normal testosterone levels at PSA failure.</p></section>

Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death

Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable‐risk prostate cancer: A secondary analysis of a randomized clinical trial

Prostate‐specific antigen nadir and testosterone level at prostate‐specific antigen failure following radiation and androgen suppression therapy for unfavorable‐risk prostate cancer and the risk of all‐cause and prostate cancer–specific mortality

Adjuvant and Salvage Radiotherapy after Prostatectomy: A Systematic Review and Meta-Analysis

The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis

The Survival Benefit of Different Lymph Node Yields in Radical Prostatectomy for Pn1m0 Prostate Cancer Patients: Implications from a Population-Based Study

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis

Outcomes of Patients with Lymph Node Metastasis Treated with Radical Prostatectomy and Adjuvant Androgen Deprivation Therapy in a Chinese Population: Results from a Cohort Study

Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer

The Impact of Multifocal Perineural Invasion on Biochemical Recurrence and Timing of Adjuvant Androgen-Deprivation Therapy in High-Risk Prostate Cancer Following Radical Prostatectomy.

Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials

Efficacy of Adjuvant and Salvage Image-Guided Radiotherapy in Post-Radical Prostatectomy Patients

Oncological Outcomes Of Patients With Ductal Adenocarcinoma Of The Prostate Receiving Radical Prostatectomy Or Radiotherapy

Use of Lymph Node Ratio to Guide Clinical Decision-Making Concerning Adjuvant Radiotherapy in Pt1-2N1 Rectal Cancer.

The Impact of Radical Prostatectomy Versus Radiation Therapy on Cancer-Specific Mortality for Nonmetastatic Prostate Cancer: Analysis of an Other-Cause Mortality Matched Cohort

Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.

Adjuvant androgen deprivation therapy loses its therapeutic benefit after premature termination: An experience of combined modality treatment on prostate cancer

Salvage Treatments for Prostate-Specific Antigen Relapse of Ct3n0m0 Prostatic Adenocarcinoma after Radical Prostatectomy Combined with Neoadjuvant Androgen Deprivation